Saatja: Marten, Swaantje <
[email protected]>
Saadetud: 03.08.2021 12:17
Koopia: Dates, Mariana <
[email protected]>; Davies, Macarena
<
[email protected]>
Teema: Short consultation on cross-border healthcare in the EU (in
relation to the European Commission's study on patients’ rights to
healthcare abroad)
Dear Madam/Sir,
I hope this email finds you well.
Our consortium, led by Tetra Tech, is currently undertaking the Study
supporting the evaluation of the Directive 2011/24/EU to ensure patient
rights in the EU in cross-border healthcare for the European Commission
(Directorate General for Health and Food Safety). I attach an information
sheet explaining the purpose of the study and the stakeholder
consultation activities envisaged in the framework of the evaluation.
Under the on the application of patients rights in cross-border
healthcare, EU nationals have the right to seek planned healthcare in
another EU country and they can claim reimbursement for treatment from
their national health system or health insurance provider. The study will
assess how the EU rules are working, in particular, as regards to giving
patients access to safe and high-quality healthcare in another EU
country.
In this context, I would like to invite you reply this very short
questionnaire on complaints or dispute resolutions procedures in relation
to patients trying to access or receiving cross-border healthcare. I
would be grateful if you can reply to me by email by Friday 3 September.
If this request should be addressed to a different
organisation/department, please provide us with their contact details.
QuestionYour answer (please be as descriptive as you can)Have cross-
border patients (this is, patients from your country trying to access or
receiving healthcare abroad) ever complained/sought redress and dispute
resolution mechanisms? If yes, were (some of) these related to treatments
under the Directive 2011/24/EU)?
If you have received complaints from cross-border patients in relation
to the Directive 2011/24/EU, were the complaints related to
administrative procedures (e.g. reimbursement, prior authorisation,
administrative burden, etc.)?
If possible, please provide the number and the nature of these complaints
If you have received complaints from cross-border patients in relation to
the Directive 2011/24/EU, were the complaints related to any harm arising
from the healthcare received?
If possible, please provide the number and the nature of these complaints
Is there anything else you would like to comment in relation to the
application of patients rights to cross-border healthcare under the
Directive 2011/24/EU?
Please indicate if you accept to be contacted again to collect further
details or clarifications on your answers.
Your contributions are very valuable for our study and we thank you in
advance for your cooperation. If you have questions or comments, please
do not hesitate in contacting us.
Best wishes,
Swaantje Marten | External Consultant, Evaluation and ResearchMobile +44
(0)7511 540812 |
UK
107 Grays Inn Road, London WC1X 8TZThe Netherlands
Jan Luijkenstraat 92-3, 1071 CT Amsterdam Poland
ul. Krucza 16/22, 00-526 Warszawa
Find out more about our work here:
Please consider the environment before printing.
Tetra Tech International Development Limited is a limited company
registered in England and Wales with registered number 03799145 and VAT
registration number 724530945. Our registered office is at 1 Northfield
Road, Reading, Berkshire, RG1 8AH, United Kingdom. Our main trading
address is 107 Grays Inn Road, London WC1X 8TZ, United Kingdom. This
message, including any attachments is intended solely for the addressee
and may contain privileged and confidential information. If you have
received this message in error, please send it back to us, and
immediately and permanently delete it. Do not use, copy or disclose the
information contained in this message or in any attachment. If you apply
to work with Tetra Tech you are actively consenting to the sharing and
processing of your data within the Tetra Tech Group and, if necessary,
with external service providers for the purposes of consideration of your
application. Your details may be retained on file for consideration for
possible future assignments. For information about how we process data
and monitor communications please see our .
Patients’ rights in cross-
border healthcare
Evaluation of the cross-border
healthcare Directive
Tetra Tech, together with empirica and Asterisk, have been commissioned by the Directorate-
General for Health and Food Safety to carry out a study to support the evaluation of the
Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare.
Under this Directive, EU nationals have the right to seek planned healthcare in another EU
country. They can also claim reimbursement for treatment from their national health system or
health insurance provider. The evaluation, and the supporting study, will assess how the EU
rules are working, in particular, as regards to:
• giving patients access to safe and high-quality healthcare in another EU country;
• encouraging cooperation between national healthcare providers, also on rare diseases and
European Reference Networks.
Your participation
We would like to invite you to contribute to the evaluation of the Directive by participating in
two consultation exercises:
• Public consultation, open until 27 July 2021 and accessible here;
• Targeted consultations to be conducted by the study team between June and September
2021. You will be invited to one or more of the following activities:
• Participate in an interview with a member of the study team;
• Complete a short survey;
• Participate in a stakeholder workshop to discuss the findings of the study.
Study timeline
May 2021 Jun Jul Aug Sep Oct Nov Dec 2021
Public Consultation Workshop Final report
Targeted consultations
#EUPatientRights
#HealthUnion